Retatrutide Research

Who Develops Retatrutide?

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library1 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide is developed by Eli Lilly and Company under the internal code LY3437943. No licensed retatrutide product exists anywhere, so there is no manufacturer of an approved medicine, only a sponsor running clinical trials.

Key facts

Developer
Eli Lilly and Company
Internal code
LY3437943
Other Lilly incretins
Tirzepatide, orforglipron, dulaglutide
Licensed product
None
Trial sponsor
Eli Lilly
Signalled filing
FDA, Q1 2027

The LY prefix

LY is Eli Lilly's development prefix, the same convention as NNC for Novo Nordisk, BI for Boehringer Ingelheim and CJC for ConjuChem. Seeing LY3437943 in a paper identifies the sponsor immediately, and this is useful to know because Lilly's incretin portfolio is unusually crowded: tirzepatide is LY3298176 and orforglipron is LY3502970.

Why the portfolio matters for reading the data

Lilly develops retatrutide, tirzepatide and orforglipron simultaneously, and they compete with each other. TRIUMPH-5 compares retatrutide against tirzepatide. A company running a head-to-head between two of its own compounds is an informative design, because there is no incentive to disadvantage either.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The confusion this creates

Three Lilly incretins with similar codes is a recipe for mixed-up citations, and this library found exactly that: a PubChem record for tirzepatide cited as retatrutide, and a trial registration for orforglipron's ATTAIN-1 labelled as retatrutide's TRIUMPH-1. Both were plausible-looking and both were wrong. Checking the compound named in a record, not just its number, is the defence.

There is no manufacturer of a product

Because no retatrutide product is licensed anywhere, there is no approved manufacturer. Material described as retatrutide and sold outside clinical trials does not originate from Lilly and has no connection to the compound in the TRIUMPH programme beyond the sequence it claims to be.

What that means here

Research material supplied under this name is synthesised by peptide manufacturers, characterised by a certificate of analysis, and supplied for laboratory use. It is not the trial compound, not a licensed medicine, and not connected to Eli Lilly.

Frequently asked questions

Who develops retatrutide?

Eli Lilly and Company, under the internal code LY3437943.

Is there an approved retatrutide product?

No. It is investigational everywhere, so there is no licensed manufacturer, only a trial sponsor.

Is research material made by Lilly?

No. It is synthesised by peptide manufacturers and supplied for laboratory use, with no connection to the trial programme.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.